These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33610444)

  • 21. Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer.
    Drangsholt S; Walter D; Ciprut S; Lepor A; Sedlander E; Curnyn C; Loeb S; Malloy P; Winn AN; Makarov DV
    Urol Oncol; 2019 Feb; 37(2):145-149. PubMed ID: 30578160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of
    Scholte M; Barentsz JO; Sedelaar JPM; Gotthardt M; Grutters JPC; Rovers MM
    Eur Urol Focus; 2020 Sep; 6(5):967-974. PubMed ID: 30826284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?
    Kulkarni SC; Sundaram PS; Padma S
    Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR.
    Rosenkrantz AB; Verma S; Choyke P; Eberhardt SC; Eggener SE; Gaitonde K; Haider MA; Margolis DJ; Marks LS; Pinto P; Sonn GA; Taneja SS
    J Urol; 2016 Dec; 196(6):1613-1618. PubMed ID: 27320841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection.
    Briganti A; Abdollah F; Nini A; Suardi N; Gallina A; Capitanio U; Bianchi M; Tutolo M; Passoni NM; Salonia A; Colombo R; Freschi M; Rigatti P; Montorsi F
    Eur Urol; 2012 Jun; 61(6):1132-8. PubMed ID: 22099610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate cancer on computed tomography: A direct comparison with multi-parametric magnetic resonance imaging and tissue pathology.
    Jia JB; Houshyar R; Verma S; Uchio E; Lall C
    Eur J Radiol; 2016 Jan; 85(1):261-267. PubMed ID: 26526901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Do patients who undergo multiparametric MRI for prostate cancer benefit from additional staging imaging? Results from a statewide collaborative.
    Eyrich NW; Tosoian JJ; Drobish J; Montie JE; Qi J; Kim T; Noyes SL; Moriarity AK; Lane BR;
    Urol Oncol; 2020 Jul; 38(7):636.e13-636.e19. PubMed ID: 32067844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
    Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
    BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imaging and Management of Prostate Cancer.
    Surasi DSS; Chapin B; Tang C; Ravizzini G; Bathala TK
    Semin Ultrasound CT MR; 2020 Apr; 41(2):207-221. PubMed ID: 32446432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population-Based Comparison of Different Risk Stratification Systems Among Prostate Cancer Patients.
    Xie M; Gao XS; Ma MW; Gu XB; Li HZ; Lyu F; Bai Y; Chen JY; Ren XY; Liu MZ
    Front Oncol; 2021; 11():646073. PubMed ID: 33928035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prevalence and locations of bone metastases using whole-body MRI in treatment-naïve intermediate- and high-risk prostate cancer.
    Ottosson F; Baco E; Lauritzen PM; Rud E
    Eur Radiol; 2021 May; 31(5):2747-2753. PubMed ID: 33141299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of imaging tests for staging newly diagnosed prostate cancer: trends from the CaPSURE database.
    Kindrick AV; Grossfeld GD; Stier DM; Flanders SC; Henning JM; Carroll PR
    J Urol; 1998 Dec; 160(6 Pt 1):2102-6. PubMed ID: 9817332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
    Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
    J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative staging of rectal cancer: pelvic MRI plus abdomen and pelvic CT. Does extrahepatic abdomen imaging matter? A case for routine thoracic CT.
    Adeyemo D; Hutchinson R
    Colorectal Dis; 2009 Mar; 11(3):259-63. PubMed ID: 18513197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified "all-in-one" imaging approach?
    Pasoglou V; Larbi A; Collette L; Annet L; Jamar F; Machiels JP; Michoux N; Vande Berg BC; Tombal B; Lecouvet FE
    Prostate; 2014 May; 74(5):469-77. PubMed ID: 24375774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort.
    KandaSwamy GV; Bennett A; Narahari K; Hughes O; Rees J; Kynaston H
    BJU Int; 2017 Nov; 120(5B):E59-E63. PubMed ID: 28317247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Appropriateness of Imaging for Low-Risk Prostate Cancer-Real World Data from the Pennsylvania Urologic Regional Collaboration (PURC).
    Mercedes R; Head D; Zook E; Eidelman E; Tomaszewski J; Ginzburg S; Uzzo R; Smaldone M; Danella J; Guzzo TJ; Lee D; Belkoff L; Walker J; Reese A; Shah MS; Jacobs B; Raman JD
    Curr Oncol; 2024 Aug; 31(8):4746-4752. PubMed ID: 39195337
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Selnæs KM; Krüger-Stokke B; Elschot M; Willoch F; Størkersen Ø; Sandsmark E; Moestue SA; Tessem MB; Halvorsen D; Kjøbli E; Angelsen A; Langørgen S; Bertilsson H; Bathen TF
    Eur Radiol; 2018 Aug; 28(8):3151-3159. PubMed ID: 29294158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of metastatic disease on
    Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
    BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer.
    Salami SS; Vira MA; Turkbey B; Fakhoury M; Yaskiv O; Villani R; Ben-Levi E; Rastinehad AR
    Cancer; 2014 Sep; 120(18):2876-82. PubMed ID: 24917122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.